MedTrace Logo

Hemoperfusion With the Efferon CT Extracorporeal Adsorbers in Patients With Severe Covid-19

NCT05104398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2021-11-03

No results posted yet for this study

Summary

Direct extracorporeal removal of inflammatory mediators with various adsorbents has been suggested as a novel treatment modality for COVID-19 patients. Study determined safety, feasibility and effectiveness of clinical use of a hemoperfusion (HP) with a novel styrene- divinylbenzene copolymer (SDC) adsorbers to remove pro-inflammatory molecules from the bloodstream of COVID-19 patients.

Conditions

Interventions

DEVICE

Efferon CT

extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules

Sponsors & Collaborators

  • Efferon JSC

    lead INDUSTRY

Principal Investigators

  • Timur Kim, MD · N.I. Pirogov Clinical City Hospital No. 1

Eligibility

Min Age
18 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-01-30
Completion
2021-07-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05104398 on ClinicalTrials.gov